title: Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis.
authors.forename: Joy
authors.initials: J
authors.lastname: Wan
authors.forename: Katrina
authors.initials: K
authors.lastname: Abuabara
authors.forename: Andrea B
authors.initials: AB
authors.lastname: Troxel
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Shin
authors.forename: Abby S
authors.initials: AS
authors.lastname: Van Voorhees
authors.forename: Bruce F
authors.initials: BF
authors.lastname: Bebo
authors.forename: Gerald G
authors.initials: GG
authors.lastname: Krueger
authors.forename: Kristina
authors.initials: K
authors.lastname: Callis Duffin
authors.forename: Joel M
authors.initials: JM
authors.lastname: Gelfand
mesh_terms: D000068879:Adalimumab; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D057186:Comparative Effectiveness Research; D003880:Dermatology / Q000706:statistics & numerical data*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy* / Q000532:radiotherapy; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000069549:Ustekinumab
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept; D008727:Methotrexate